Supramolecular nanostructures that mimic VEGF as a strategy for ischemic tissue repair

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 33, 2011, Pages 13438-13443

  Webber, Matthew J ^a   Tongers, Jörn ^b,c   Newcomb, Christina J ^a   Marquardt, Katja Theres ^b   Bauersachs, Johann ^c   Losordo, Douglas W ^b   Stupp, Samuel I ^a,b,d,e  

^a Northwestern University   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d NORTHWESTERN UNIVERSITY   (United States)

^e Institute for Bionanotechnology in Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOPHILE; ANGIOGENIC FACTOR; NANOFIBER; NANOMATERIAL; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHICK EMBRYO; CONTROLLED STUDY; CONVALESCENCE; EMBRYO; ENDOTHELIUM CELL; ENDURANCE; HINDLIMB; HUMAN; HUMAN CELL; IMMUNOHISTOLOGY; LEG ISCHEMIA; LIMB SALVAGE; MICROCIRCULATION; MOUSE; NANOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; SUPRAMOLECULAR CHEMISTRY; TISSUE PERFUSION; TREADMILL EXERCISE;

ANGIOGENIC PROTEINS; ANIMALS; CELL LINE; CHICK EMBRYO; ENDOTHELIUM, VASCULAR; HUMANS; ISCHEMIA; MICE; MOLECULAR MIMICRY; NANOSTRUCTURES; NEOVASCULARIZATION, PHYSIOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

EID: 80051967814     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1016546108     Document Type: Article

References (48)

1. Lloyd-Jones D., et al. (2009) Heart disease and stroke statistics - 2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119:480-486.
2. Folkman J. (2007) Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov 6:273-286.
3. Ferrara N., Gerber H.P., LeCouter J. (2003) The biology of VEGF and its receptors. Nat Med 9:669-676. (Pubitemid 36749215)
4. Gupta R., Tongers J., Losordo D.W. (2009) Human studies of angiogenic gene therapy. Circ Res 105:724-736.
5. Yla-Herttuala S., Rissanen T.T., Vajanto I., Hartikainen J. (2007) Vascular endothelial growth factors: Biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol 49:1015-1026. (Pubitemid 46349500)
6. Laham R.J., et al. (1999) Intracoronary and intravenous administration of basic fibroblast growth factor: Myocardial and tissue distribution. Drug Metab Dispos 27:821-826. (Pubitemid 29297781)
7. Lu E., et al. (2003) Targeted in vivo labeling of receptors for vascular endothelial growth factor: Approach to identification of ischemic tissue. Circulation 108:97-103. (Pubitemid 36859027)
8. Post M.J., Laham R., Sellke F.W., Simons M. (2001) Therapeutic angiogenesis in cardiology using protein formulations. Cardiovasc Res 49:522-531. (Pubitemid 32146415)
9. Hartgerink J.D., Beniash E., Stupp S.I. (2001) Self-assembly and mineralization of peptideamphiphile nanofibers. Science 294:1684-1688.
10. Hartgerink J.D., Beniash E., Stupp S.I. (2002) Peptide-amphiphile nanofibers: A versatile scaffold for the preparation of self-assembling materials. Proc Natl Acad Sci USA 99:5133-5138. (Pubitemid 34411515)
11. Webber M.J., Kessler J.A., Stupp S.I. (2010) Emerging peptide nanomedicine to regenerate tisues and organs. J Intern Med 267:71-88.
12. Cui H., Webber M.J., Stupp S.I. (2010) Self-assembly of peptide amphiphiles: From molecules to nanostructures to biomaterials. Biopolymers 94:1-18.
13. Webber M.J., et al. (2010) Development of bioactive peptide amphiphiles for therapeutic cell delivery. Acta Biomater 6:3-11.
14. Silva G.A., et al. (2004) Selective differentiation of neural progenitor cells by high-epitope density nanofibers. Science 303:1352-1355. (Pubitemid 38269424)
15. Muraoka T., Koh C.Y., Cui H., Stupp S.I. (2009) Light-triggered bioactivity in three dimensions. Angew Chem Int Ed Engl 48:5946-5949.
16. Tovar J.D., Claussen R.C., Stupp S.I. (2005) Probing the interior of peptide amphiphile supramolecular aggregates. J Am Chem Soc 127:7337-7345. (Pubitemid 40753583)
17. Ghanaati S., et al. (2009) Dynamic in vivo biocompatibility of angiogenic peptide amphiphile nanofibers. Biomaterials 30:6202-6212.
18. Tysseling-Mattiace V.M., et al. (2008) Self-assembling nanofibers inhibit glial scar formation and promote axon elongation after spinal cord injury. J Neurosci 28:3814-3823.
19. Webber M.J., et al. (2010) Capturing the stem cell paracrine effect using heparinpresenting nanofibres to treat cardiovascular diseases. J Tissue Eng Regen Med 4:600-610.
20. Chen R.R., et al. (2007) Integrated approach to designing growth factor delivery systems. FASEB J 21:3896-3903. (Pubitemid 350232347)
21. Silva E.A., Mooney D.J. (2007) Spatiotemporal control of vascular endothelial growth factor delivery from injectable hydrogels enhances angiogenesis. J Thromb Haemost 5:590-598. (Pubitemid 46680694)
22. Silva E.A., Mooney D.J. (2010) Effects of VEGF temporal and spatial presentation on angiogenesis. Biomaterials 31:1235-1241.
23. Garbern J.C., Hoffman A.S., Stayton P.S. (2010) Injectable pH- and temperature-responsive poly(N-isopropylacrylamide-co-propylacrylic acid) copolymers for delivery of angiogenic growth factors. Biomacromolecules 11:1833-1839.
24. Tae G., Scatena M., Stayton P.S., Hoffman A.S. (2006) PEG-cross-linked heparin is an affinity hydrogel for sustained release of vascular endothelial growth factor. J Biomater Sci Polym Ed 17:187-197. (Pubitemid 44069724)
25. Rajangam K., et al. (2006) Heparin binding nanostructures to promote growth of blood vessels. Nano Lett 6:2086-2090. (Pubitemid 44555259)
26. Zisch A.H., et al. (2003) Cell-demanded release of VEGF from synthetic, biointeractive cell ingrowth matrices for vascularized tissue growth. FASEB J 17:2260-2262. (Pubitemid 39561459)
27. Zisch A.H., Schenk U., Schense J.C., Sakiyama-Elbert S.E., Hubbell J.A. (2001) Covalently conjugated VEGF - fibrin matrices for endothelialization. J Control Release 72:101-113. (Pubitemid 32522348)
28. D'Andrea L.D., Del Gatto A., Pedone C., Benedetti E. (2006) Peptide-based molecules in angiogenesis. Chem Biol Drug Des 67:115-126. (Pubitemid 43881373)
29. Ferrara N., Kerbel R.S. (2005) Angiogenesis as a therapeutic target. Nature 438:967-974. (Pubitemid 43093963)
30. D'Andrea L.D., et al. (2005) Targeting angiogenesis: Structural characterization and biological properties of a de novo engineered VEGF mimicking peptide. Proc Natl Acad Sci USA 102:14215-14220. (Pubitemid 41429678)
31. Diana D., et al. (2008) Structural determinants of the unusual helix stability of a de novo engineered vascular endothelial growth factor (VEGF) mimicking peptide. Chemistry 14:4164-4166.
32. Malkar N.B., Lauer-Fields J.L., Juska D., Fields G.B. (2003) Characterization of peptideamphiphiles possessing cellular activation sequences. Biomacromolecules 4:518-528. (Pubitemid 36701220)
33. Matsumoto T., Claesson-Welsh L. (2001) VEGF receptor signal transduction. Sci STKE 2001:re21.
34. Duval M., Bedard-Goulet S., Delisle C., Gratton J.P. (2003) Vascular endothelial growth factor-dependent down-regulation of Flk-1/KDR involves Cbl-mediated ubiquitination. Consequences on nitric oxide production from endothelial cells. J Biol Chem 278:20091-20097. (Pubitemid 36799203)
35. Yancopoulos G.D., et al. (2000) Vascular-specific growth factors and blood vessel formation. Nature 407:242-248.
36. Kofidis T., et al. (2002) Restoration of blood flow and evaluation of corresponding angiogenic events by scanning electron microscopy after a single dose of VEGF in a model of peripheral vascular disease. Angiogenesis 5:87-92. (Pubitemid 36076927)
37. Wang X., Horii A., Zhang S. (2008) Designer functionalized self-assembling peptide nanofiber scaffolds for growth, migration, and tubulogenesis of human umbilical vein endothelial cells. Soft Matter 4:2388-2395.
38. Vance D., Martin J., Patke S., Kane R.S. (2009) The design of polyvalent scaffolds for targeted delivery. Adv Drug Deliv Rev 61:931-939.
39. Czajkowsky D.M., Shao Z. (2009) The human IgM pentamer is a mushroom-shaped molecule with a flexural bias. Proc Natl Acad Sci USA 106:14960-14965.
40. Douglas T., YoungM.(2006) Viruses: Making friends with old foes. Science 312:873-875. (Pubitemid 43727311)
41. Hynes R.O. (2009) The extracellular matrix: Not just pretty fibrils. Science 326:1216-1219.
42. Galeazzi S., et al. (2009) Multivalent supramolecular dendrimer-based drugs. Biomacromolecules 11:182-186.
43. Mammen M., Choi S.K., Whitesides G.M. (1998) Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew Chem Int Ed Engl 37:2755-2794.
44. Rao J., Lahiri J., Isaacs L., Weis R.M., Whitesides G.M. (1998) A trivalent system from vancomycin. D-ala-D-Ala with higher affinity than avidin.biotin. Science 280:708-711. (Pubitemid 28243338)
45. Helms B.A., et al. (2009) High-affinity peptide-based collagen targeting using synthetic phage mimics: From phage display to dendrimer display. J Am Chem Soc 131:11683-11685.
46. Vance D., Shah M., Joshi A., Kane R.S. (2008) Polyvalency: A promising strategy for drug design. Biotechnol Bioeng 101:429-434.
47. Cwirla S.E., et al. (1997) Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science 276:1696-1699. (Pubitemid 27421976)
48. Johnson D.L., et al. (1997) Amino-terminal dimerization of an erythropoietin mimetic peptide results in increased erythropoietic activity. Chem Biol 4:939-950. (Pubitemid 28050378)